Cingulate Inc.
CTx-1301
ADHD
Resolved
37days ago
FDA decision · May 31, 2026
What's at stake
The FDA's approval decision on CTx-1301 for ADHD is due May 31, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“In October 2025, Cingulate announced that the U.S. Food and Drug Administration (FDA) had accepted for review the New Drug Application (NDA) for CTx-1301 and had assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31”